Regeneron Pharmaceuticals, Inc.

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 7, 2026), Regeneron Pharmaceuticals, Inc. reported 3 stock positions worth $177.2 million. Its top holding was Parabilis Medicines (PBLS) at 64.4% of the portfolio, followed by Intellia Therapeutics (NTLA, 35.4%) and Adicet Bio (ACET, 0.3%). Compared with Q1 2026, it opened 2 new positions and sold out of 1. The biggest buy was a new position in Parabilis Medicines (PBLS) and the biggest sale an exit from Adicet Bio (ACET).

Most Recent 13F
Q2 2026
Location
TARRYTOWN, NY
CIK
0000872589
Portfolio Value
$177.2M (Q2 2026)
SEC Filing
0001104659-26-092709 ↗ filed Aug 7, 2026

Holdings Value

0$500.0M$1.0B$1.5B Q4 2024: $1.1B Q4 2024 Q1 2025: $1.2B Q1 2025 Q2 2025: $1.5B Q2 2025 Q3 2025: $700.4M Q3 2025 Q4 2025: $33.8M Q4 2025 Q1 2026: $47.9M Q1 2026 Q2 2026: $177.2M $177.2M Q2 2026

Holdings 3 stocks · $177.2M
PBLS Parabilis Medicines Inc. 64.35% 4,166,666 $114.0M New
NTLA Intellia Therapeutics Inc. 35.35% 3,702,995 $62.7M No change
ACET Adicet Bio Inc. 0.29% 60,511 $523K New

Portfolio Sells Q1 2026 → Q2 2026
ACET Adicet Bio Inc. Sold out 0.00% −0.86

Portfolio Buys Q1 2026 → Q2 2026
PBLS Parabilis Medicines Inc. New 64.35% +64.35
ACET Adicet Bio Inc. New 0.29% +0.29

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.2MPBLS, NTLA, ACET
Q1 2026 2$47.9MNTLA, ACET
Q4 2025 2$33.8MNTLA, ACET
Q3 2025 4$700.4MALNY, NTLA, ADVM, ACET
Q2 2025 4$1.5BALNY, NTLA, ACET, ADVM
Q1 2025 6$1.2BALNY, NTLA, TSVT, ADVM, ACET
Q4 2024 6$1.1BALNY, NTLA, TSVT, ACET, ADVM